40
Participants
Start Date
September 12, 2024
Primary Completion Date
December 31, 2025
Study Completion Date
December 12, 2030
Camrelizumab
200 mg, intravenously, 20-60 min. 2 times, every 21 days
Paclitaxel-albumin
260 mg/m² over 30 min, 3 times, every 21 days
Cisplatin
4 h, 75-80 mg/m², 3 times, every 21 days
radical surgery
Radical hysterectomy + pelvic lymphadenectomy 士 para-aortic lymphadenectomy
RECRUITING
Anhui Provincial Cancer Hospital, Hefei
RECRUITING
Women's Hospital, Zhejiang University School of Medicine, Hangzhou
RECRUITING
Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou
RECRUITING
The First Affiliated Hospital (Southwest Hospital), Army Medical University (Third Military Medical University), Chongqing
RECRUITING
Xiangya Hospital, Central South University, Changsha
RECRUITING
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
RECRUITING
The Affiliated Tumor Hospital of Guangxi Medical University, Nanning
RECRUITING
Second People's Hospital of Sichuan (Sichuan Cancer Hospital), Chengdu
RECRUITING
Gansu Provincial Maternity and Child-care Hospital, Lanzhou
RECRUITING
Beiing Friendship Hospital, Capital Medical University, Beijing
RECRUITING
Shengjing Hospital of China Medical University, Shenyang
RECRUITING
Tianjin Medical University General Hospital, Tianjin
Southwest Hospital, China
OTHER
Women's Hospital School Of Medicine Zhejiang University
OTHER
Anhui Provincial Cancer Hospital
OTHER
Sichuan Cancer Hospital and Research Institute
OTHER
Gansu Provincial Maternal and Child Health Care Hospital
OTHER
Beijing Friendship Hospital
OTHER
Tianjin Medical University General Hospital
OTHER
Xiangya Hospital of Central South University
OTHER
West China Second University Hospital
OTHER
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
OTHER
Zhejiang Cancer Hospital
OTHER
Shengjing Hospital
OTHER
Qilu Hospital of Shandong University
OTHER
Cancer Hospital of Guangxi Medical University
OTHER
Tongji Hospital
OTHER